Literature DB >> 19858501

Unintended hepatic adverse events associated with cancer chemotherapy.

John R Senior1.   

Abstract

Chemotherapy is meant to be toxic, but it is particularly aimed at the tumor cells. Collateral damage may occur to normal cells and tissues, especially if they are fairly rapidly regenerating, as is the case for bone marrow cells, intestinal epithelial cells, and liver cells after hepatic injury. The liver has a great capacity to resist injury, overcome it, and to regenerate, even after quite massive injury (resection of 50%-65%, for example). This capacity may make it susceptible to chemotherapeutic toxicity, and a struggle between injury and adaptation, leading to recovery and tolerance or to failure and death. If the chemotherapy is aimed just at delaying progression of the cancer for a few weeks or months, it may not be worth the risk of irreversible liver injury developing in that time. Close clinical observation and sound clinical judgment are required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858501     DOI: 10.1177/0192623309351719

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  4 in total

1.  Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.

Authors:  Bruce M Psaty
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

2.  Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles.

Authors:  Adam J Cole; Allan E David; Jianxin Wang; Craig J Galbán; Victor C Yang
Journal:  Biomaterials       Date:  2011-09       Impact factor: 12.479

Review 3.  Hepatotoxicity Secondary to Chemotherapy.

Authors:  Alla Grigorian; Christopher B O'Brien
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

4.  Incidence and risk of regorafenib-induced hepatotoxicity.

Authors:  Bin Zhao; Hong Zhao
Journal:  Oncotarget       Date:  2017-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.